Relay Therapeutics Reports Q3 2026 Financial Results
Relay Therapeutics, Inc. reported third-quarter revenue of $0, missing the FactSet consensus estimate of $1.6 million.
Jones Trading Maintains Buy on Relay Therapeutics, Raises Price Target to $31
Jones Trading Maintains Buy on Relay Therapeutics, Raises Price Target to $31(摘要待生成)
Relay Therapeutics Q3 EPS $(0.37) Beats $(0.40) Estimate
Relay Therapeutics Q3 EPS $(0.37) Beats $(0.40) Estimate(摘要待生成)
Relay Therapeutics files Q3 2026 Form 10-Q
Filed Nov. 4 for the quarter ended Sept. 30: Relay reported $848.6M in cash, equivalents and investments and $238.7M net loss for the first nine months of 2026. It said it had sold 16,006,569 shares through its ATM for $159.2M net proceeds as of Sept. 30; the ATM program was increased to $463M in August 2026.
Relay Therapeutics, 8-K (2.02, 9.01): reported results of operations
Relay Therapeutics reported third-quarter 2026 results, with approximately $849 million in cash, cash equivalents and investments, projected mid-2027 enrollment completion for its Phase 3 breast cancer trial, and updates on vascular-anomaly programs and commercial preparations.